株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脂質異常症 - 世界の医薬品予測・市場分析

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

発行 GlobalData 商品コード 336855
出版日 ページ情報 英文 356 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.16円で換算しております。
Back to Top
脂質異常症 - 世界の医薬品予測・市場分析 PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025
出版日: 2016年12月13日 ページ情報: 英文 356 Pages
概要

世界における脂質異常症 (高脂血症) 治療薬市場は2015年に112億米ドルに達し、調査対象期間中10.1%の複合年間成長率(CAGR)で成長し、2025年までに293億米ドルに到達することが見込まれています。

当レポートでは、世界の脂質異常症 (高脂血症) 市場について調査し、脂質異常症の概要、治療薬の年間市場収益・年間コスト・利用パターンに関するデータ・予測、アンメットニーズ、R&D・臨床試験の評価、パイプライン分析、および現在・将来の競合状況の分析などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理学
  • 症状
  • 予後
  • 生活の質

第4章 疫学

  • 疾病の背景
  • リスク因子・併存疾患
  • 世界の動向
  • 歴史的な動向
  • 予測手法
    • 調査に利用する情報源
    • 予測の前提条件・手法
  • 脂質異常症の疫学的予測
    • 脂質異常症の疫学的予測
    • 家族性高コレステロール血症の疫学的予測
    • 高LDLコレステロール血症の疫学的予測
    • 高トリグリセリドの疫学的予測
    • 超高トリグリセリドの疫学的予測
    • 低HDLコレステロールの疫学的予測
  • ディスカッション
    • 疫学的予測の考察
    • 分析の制限
    • 分析の強味

第5章 疾病管理

  • 診断・治療の概要
    • 診断
    • 治療ガイドライン・主な処方薬
    • 臨床診療
  • 米国
  • EU5カ国
  • 日本

第6章 競合評価

  • 製品概要
  • スタチン
  • ゼチーア (エゼチミブ)
  • プラルエント(アリオクマブ)
  • レパサ(エボロクマブ)
  • バイトリン (シンバスタチン/エゼチミブ)
  • キナムロ(ミポメルセンナトリウム)
  • ジャクスタピッド (ロミタピド)
  • ナイアシン/ニコチン酸
  • フィブラート
  • オメガ‐3脂肪酸
  • 胆汁酸抑制薬

第7章 アンメットニーズ・機会

  • 概要
  • リポタンパク質を対象とした治療
  • コスト効率のよい治療
  • 有効なトリグリセリド濃度低下治療
  • 改善した診断、患者教育、長期コンプライアンス
  • 副作用の少ないHoFH治療
  • アテロームプラーク増加予防・阻害治療

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床開発中の有望な薬剤
    • LY3015014
    • Anacetrapib
    • AMG-899 (TA-8995/DEZ-001)
    • Bempedoic Acid (ETC-1002)
    • Volanesorsen
    • CER-001
    • ALN-PCSsc
    • Gemcabene
    • Pemafibrate (K-877)
  • その他の開発中の薬剤

第9章 現在・将来の企業

  • 概要
  • 企業戦略における動向
  • 企業プロファイル
    • AbbVie
    • Aegerion Pharmaceuticals, Inc.
    • Akcea Therapeutics, Inc. and Ionis Pharmaceuticals
    • Amarin
    • Amgen
    • AstraZeneca
    • Cerenis Therapeutics Inc.
    • 第一三共
    • Eli Lilly
    • Esperion Therapeutics, Inc.
    • Genzyme
    • Merck & Co.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi
    • The Medicines Company

第10章 市場展望

  • 世界市場
    • 予測
    • 促進因子・阻害因子
  • 米国
  • EU5カ国
  • 日本

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in the dyslipidemia market in the 7MM, reaching peak sales of $9.5B in 2025.

Major drivers of Dyslipidemia market growth over the forecast period are -

  • The launches of three PCSK9 inhibitors-Amgen's Repatha, Sanofi and Regeneron's Praluent, and Eli Lilly's LY3015014-which will significantly boost market growth.
  • The launch of several add-on therapies, including Esperion Therapeutic's ETC-1002 and Merck and Amgen's cholesteryl ester transfer protein (CETP) inhibitors
  • Increase in global prevalence of dyslipidemia, coupled with growing awareness of the disease.

Although the dyslipidemia market has numerous well-established therapies and the pipeline is promising, there is a considerable level of unmet need. Patient compliance, cost-effective therapies, and drugs targeting rare diseases represent major unmet needs in the dyslipidemia space. Patient compliance remains the biggest issue, and a major contributing factor to this is the asymptomatic nature of this disease, as well as the burden of taking several pills daily to treat this disease.

In addition to this, many patients discontinue therapy, which puts them at considerable risk of experiencing a CV event. The PCSK9 monoclonal antibodies (mAbs), Repatha and Praluent, are expected to address the compliance issue due to their less frequent dosing schedules; however, KOLs indicated that patient education and enhanced disease awareness are important issues that also need to be addressed. While patient education is not a common area of focus for pharmaceutical companies, it's clear that if diagnosis rates and patient compliance were increased, then this would translate to a boost in drug use and sales.

Companies reviewed in this report: Abbvie, Aegerion Pharmaceuticals Inc., Akcea Therapeutics Inc., Amarin, Amgen, AstraZeneca, Cerenis Therapeutics Inc., Daiichi Sankyo, Eli Lilly, Esperion Therapeutics Inc., Genzyme, Ionis Pharmaceuticals, Merck & Co., Regeneron Pharmaceuticals Inc., Sanofi, The Medicine Company.

Scope

  • Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the dyslipidemia therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM dyslipidemia therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used Tables
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for Dyslipidemia (2015-2025)
    • 4.5.1. Dyslipidemia
    • 4.5.2. Familial Hypercholesterolemia
    • 4.5.3. Increased Low-Density Lipoprotein Cholesterol
    • 4.5.4. High Triglycerides
    • 4.5.5. Very High Triglycerides
    • 4.5.6. Low High-Density Lipoprotein Cholesterol
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Statins
    • 6.2.1. Overview of drug class
    • 6.2.2. Crestor (Rosuvastatin)
  • 6.3. Zetia (Ezetimibe)
    • 6.3.1. Overview
    • 6.3.2. Efficacy
    • 6.3.3. Safety

6.3.4. SWOT Analysis

    • 6.3.5. Forecast
  • 6.4. Praluent (Alirocumab)
    • 6.4.1. Overview
    • 6.4.2. Efficacy
    • 6.4.3. Safety

6.4.4. SWOT Analysis

    • 6.4.5. Forecast
  • 6.5. Repatha (Evolocumab)
    • 6.5.1. Overview
    • 6.5.2. Efficacy
    • 6.5.3. Safety

6.5.4. SWOT Analysis

    • 6.5.5. Forecast
  • 6.6. Vytorin (Simvastatin/Ezetimibe)
    • 6.6.1. Overview
    • 6.6.2. Efficacy
    • 6.6.3. Safety

6.6.4. SWOT Analysis

    • 6.6.5. Forecast
  • 6.7. Kynamro (Mipomersen)
    • 6.7.1. Overview
    • 6.7.2. Efficacy
    • 6.7.3. Safety

6.7.4. SWOT Analysis

    • 6.7.5. Forecast
  • 6.8. Juxtapid (Lomitapide)
    • 6.8.1. Overview
    • 6.8.2. Efficacy
    • 6.8.3. Safety

6.8.4. SWOT Analysis

    • 6.8.5. Forecast
  • 6.9. Niacin/Nicotinic Acid
    • 6.9.1. Overview
    • 6.9.2. Efficacy
    • 6.9.3. Safety

6.9.4. SWOT Analysis

    • 6.9.5. Forecast
  • 6.10. Fibrates
    • 6.10.1. Overview of Drug Class
    • 6.10.2. Tricor/Trilipix (Fenofibrate/Fenofibric acid)
  • 6.11. Omega-3 Fatty Acids
    • 6.11.1. Overview
    • 6.11.2. Lovaza (omega-3 acid ethyl esters)
    • 6.11.3. Vascepa (Icosapent Ethyl)
    • 6.11.4. Epanova (omega-3 carboxylic acids)
  • 6.12. Bile Acid Sequestrants
    • 6.12.1. Overview
    • 6.12.2. Efficacy
    • 6.12.3. Safety

6.12.4. SWOT Analysis

    • 6.12.5. Forecast

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Therapies that Target Lipoprotein(a)
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Cost-Effective Therapies for Dyslipidemia
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Efficacious TG-Lowering Therapies
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Improved Diagnosis, Patient Education, and Long-Term Compliance
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. HoFH Therapies with Reduced Side Effects
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Therapies that Prevent or Reverse the Buildup of Atherosclerotic Plaque
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. LY3015014
    • 8.2.2. Anacetrapib
    • 8.2.3. AMG-899(TA-8995/DEZ-001)
    • 8.2.4. Bempedoic Acid (ETC-1002)
    • 8.2.5. Volanesorsen
    • 8.2.6. CER-001
    • 8.2.7. ALN-PCSsc
    • 8.2.8. Gemcabene
    • 8.2.9. Pemafibrate (K-877)
  • 8.3. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. AbbVie
    • 9.3.2. Aegerion Pharmaceuticals, Inc.
    • 9.3.3. Akcea Therapeutics, Inc. and Ionis Pharmaceuticals
    • 9.3.4. Amarin
    • 9.3.5. Amgen
    • 9.3.6. AstraZeneca
    • 9.3.7. Cerenis Therapeutics, Inc.
    • 9.3.8. Daiichi Sankyo
    • 9.3.9. Eli Lilly
    • 9.3.10. Esperion Therapeutics, Inc.
    • 9.3.11. Genzyme
    • 9.3.12. Merck & Co.
    • 9.3.13. Regeneron Pharmaceuticals, Inc.
    • 9.3.14. Sanofi
    • 9.3.15. The Medicines Company

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Dyslipidemia Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Director of Epidemiology
    • 11.7.5. Global Director of Therapy Analysis and Epidemiology
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Dyslipidemia: Fredrickson Classification System
  • Table 2: Risk Factors and Comorbidities for Dyslipidemia
  • Table 3: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia
  • Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH
  • Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C
  • Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG
  • Table 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C
  • Table 8: 8MM, Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 9: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 10: 8MM, Total Prevalent Cases of Increased LDL-C, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025
  • Table 11: 8MM, Total Prevalent Cases of High TG, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025
  • Table 12: 8MM, Total Prevalent Cases of Very High TG, Ages ≥20 Years, Both Sexes, N, Selected Years, 2015-2025
  • Table 13: 8MM, Total Prevalent Cases of Low HDL-C, Ages ≥20 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 14: AACE Optimal/Near-Optimal, Borderline, and High-Risk Serum Lipid Concentrations
  • Table 15: Factors Considered for Different CVD Risk Calculators
  • Table 16: Treatment Guidelines for Dyslipidemia
  • Table 17: Most Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2015
  • Table 18: Country Profile - US
  • Table 19: Market Profile - 5EU
  • Table 20: Country Profile - Japan
  • Table 21: Intensity level of commonly used statins
  • Table 22: Product Profile - Crestor (Rosuvastatin)
  • Table 23: Efficacy of Rosuvastatin - Lipid and Lipoprotein Parameters
  • Table 24: Crestor SWOT Analysis, 2015
  • Table 25: Product Profile - Zetia
  • Table 26: Efficacy of Zetia - Primary and Secondary Endpoints, IMPROVE-IT study
  • Table 27: Safety of Zetia (Ezetimibe)
  • Table 28: Drug Zetia (Ezetimibe) SWOT Analysis, 2015-2025
  • Table 29: Product Profile - Praluent
  • Table 30: Efficacy of Praluent (alirocumab) - Primary and Secondary Endpoints, ODYSSEY LONG TERM Phase III Study
  • Table 31: Safety of Praluent (alirocumab)
  • Table 32: Praluent (Alirocumab) SWOT Analysis, 2015-2025
  • Table 33: Product Profile - Repatha
  • Table 34: Pivotal Trials of Repatha (Evolocumab)
  • Table 35: Repatha (Evolocumab) SWOT Analysis, 2015-2025
  • Table 36: Product Profile - Vytorin
  • Table 37: Efficacy of Vytorin - Primary and Secondary Endpoints, VYVA study
  • Table 38: Vytorin SWOT Analysis, 2015
  • Table 39: Product Profile - Kynamro
  • Table 40: Efficacy of Kynamro - Lipid and Lipoprotein Parameters, RADICHOL 1 Phase III Study
  • Table 41: Safety of Kynamro (mipomersen)
  • Table 42: Kynamro SWOT Analysis, 2015
  • Table 43: Product Profile - Juxtapid
  • Table 44: Efficacy of Juxtapid - Lipid and Lipoprotein parameters, Phase III Study
  • Table 45: Juxtapid SWOT Analysis, 2015
  • Table 46: Product Profile - Niaspan
  • Table 47: Niacin/Nicotinic Acid SWOT Analysis, 2015
  • Table 48: Summary of the Therapeutic Properties of Fibrates*
  • Table 49: Product Profile - Tricor/Trilipix
  • Table 50: Tricor/Trilipix SWOT Analysis, 2015
  • Table 51: Product Profile - Lovaza
  • Table 52: Efficacy of Lovaza - Pivotal Studies for the Treatment of Very High TGs
  • Table 53: Lovaza SWOT Analysis, 2015
  • Table 54: Product Profile - Vascepa
  • Table 55: Efficacy of Vascepa - ANCHOR Phase III Study
  • Table 56: Vascepa SWOT Analysis, 2015
  • Table 57: Product Profile - Epanova
  • Table 58: Efficacy of Epanova - ESPRIT Phase III Study
  • Table 59: Epanova SWOT Analysis, 2015
  • Table 60: Product Profile - Welchol
  • Table 61: Efficacy of Welchol - GLOWS Study
  • Table 62: Welchol SWOT Analysis, 2015
  • Table 63: Unmet Need and Opportunity in Dyslipidemia, 2015
  • Table 64: Product Profile - LY3015014
  • Table 65: Efficacy of LY3015014
  • Table 66: LY3015014 SWOT Analysis, 2015
  • Table 67: Product Profile - Anacetrapib
  • Table 68: Efficacy of Anacetrapib - Primary and Secondary Endpoints, DEFINE study
  • Table 69: Safety of Anacetrapib - AEs and Safety Variables, DEFINE study
  • Table 70: Anacetrapib SWOT Analysis, 2015
  • Table 71: Product Profile - AMG-899 ( TA-8995/DEZ-001)
  • Table 72: Efficacy of TA-8995 - Primary Endpoints, TULIP study
  • Table 73: AMG-899 SWOT Analysis, 2015
  • Table 74: Product Profile - ETC-1002 (Bempedoic Acid)
  • Table 75: Efficacy of ETC-1002 - Lipid and lipoprotein parameters
  • Table 76: ETC-1002 SWOT Analysis, 2015
  • Table 77: Product Profile - Volanesorsen
  • Table 78: Efficacy of Volanesorsen - Lipid and Lipoprotein Levels and Glycemic Control
  • Table 79: Volanesorsen SWOT Analysis, 2015
  • Table 80: Product Profile - CER-001
  • Table 81: Efficacy of CER-001
  • Table 82: CER-001 SWOT Analysis, 2015
  • Table 83: Product Profile - ALN-PCSsc
  • Table 84: ALN-PCSsc SWOT Analysis, 2015
  • Table 85: Product Profile - Gemcabene
  • Table 86: Efficacy of Gemcabene
  • Table 87: Gemcabene SWOT Analysis, 2015
  • Table 88: Product Profile - Pemafibrate
  • Table 89: Efficacy of Pemafibrate
  • Table 90: Safety of Pemafibrate
  • Table 91: Pemafibrate SWOT Analysis, 2015
  • Table 92: Drugs in Development for Dyslipidemia, 2015
  • Table 93: Key Companies in the Dyslipidemia Market in the 7MM, 2015
  • Table 94: Abbvie's Dyslipidemia Portfolio Assessment, 2015
  • Table 95: Aegerion Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015
  • Table 96: Ionis Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015
  • Table 97: Amarin's Dyslipidemia Portfolio Assessment, 2015
  • Table 98: Amgen's Dyslipidemia Portfolio Assessment, 2015
  • Table 99: AstraZeneca's Dyslipidemia Portfolio Assessment, 2015
  • Table 100: Cerenis Therapeutics' Dyslipidemia Portfolio Assessment, 2015
  • Table 101: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2015
  • Table 102: Eli Lilly's Dyslipidemia Portfolio Assessment, 2015
  • Table 103: Esperion Therapeutics' Dyslipidemia Portfolio Assessment, 2015
  • Table 104: Genzyme's Dyslipidemia Portfolio Assessment, 2015
  • Table 105: Merck & Co.'s Dyslipidemia Portfolio Assessment, 2015
  • Table 106: Regeneron Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015
  • Table 107: Sanofi's Dyslipidemia Portfolio Assessment, 2015
  • Table 108: The Medicines Company's Dyslipidemia Portfolio Assessment, 2015
  • Table 109: Dyslipidemia Market - Global Drivers and Barriers, 2015?2025
  • Table 110: Key Events Impacting Sales for Dyslipidemia in the US, 2015-2025
  • Table 111: Dyslipidemia Market - Drivers and Barriers in the US, 2015?2025
  • Table 112: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2015-2025
  • Table 113: Dyslipidemia Market - Drivers and Barriers in the 5EU, 2015?2025
  • Table 114: National Healthcare Authorities in the 5EU Nations
  • Table 115: National Public Health Initiatives in the 5EU Nations
  • Table 116: Governmental Drug Pricing Authorities in the 5EU Nations
  • Table 117: Key Events Impacting Sales for Dyslipidemia in Japan, 2015-2025
  • Table 118: Dyslipidemia Market - Drivers and Barriers in Japan, 2015?2025
  • Table 119: Key Launch Dates for Dyslipidemia
  • Table 120: Key Patent Expiry Dates for Dyslipidemia
  • Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Classification of Dyslipidemia
  • Figure 2: 8MM Total Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, 2015-2025
  • Figure 3: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages ≥20 Years, Both Sexes, N, 2015-2025
  • Figure 4: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages ≥20 Years, N, 2015 and 2025
  • Figure 5: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, N, 2015 and 2025
  • Figure 6: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 8: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 9: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 10: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 11: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ≥20 Years, 2015
  • Figure 12: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages ≥20 Years, 2015
  • Figure 13: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 14: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 15: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages ≥20 Years, N, 2015
  • Figure 16: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 17: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages ≥20 Years, 2015
  • Figure 18: Statin Mechanism of Action
  • Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2015-2025
  • Figure 20: ACL inhibition
  • Figure 21: Company Portfolio Gap Analysis in Dyslipidemia, 2015-2025
  • Figure 22: Global Sales for Dyslipidemia by Region, 2015 and 2025
  • Figure 23: Global Sales for Dyslipidemia by Drug Class, 2015 and 2025
  • Figure 24: Global Sales for PCSK9 targeting therapies, 2015-2025
  • Figure 25: Sales for Dyslipidemia by Drug Class in the US, 2015 and 2025
  • Figure 26: Sales for Dyslipidemia by Drug Class in the 5EU, 2015 and 2025
  • Figure 27: Sales for Dyslipidemia by Drug Class in Japan, 2015 and 2025
Back to Top